AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05875545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Exercises
Description: Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
Study NCT06423989 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IVIG
Description: treatment of subfertility
Study NCT04186169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation
Study NCT06478719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule
Study NCT06478719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT06478719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB-1603
Description: FB-1603 (165 mg/cap) oral capsule
Study NCT05539404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment in addition of best medical treatment.
Description: Endovascular treatment (EVT) of acute ischemic stroke (AIS) related to an anterior large cerebral vessel occlusion (LVO)
Study NCT04917692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 2.5 mg daily
Study NCT05102903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR1016A
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study NCT05102903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR1016B
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study NCT05420662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation of vagina during abdominal hysterectomy operation
Description: The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.
Study NCT05420662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical conventional abdominal hysterectomy operation
Description: Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
Study NCT05540080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with applicators C4/C5 to the BTL-899 system.
Study NCT05507008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kenetik Ketone Drink
Description: BHB supplementation
Study NCT04582487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bone marrow and/or peripheral blood samples withdrawal
Description: bone marrow and/or peripheral blood samples evaluation
Study NCT05715801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
Study NCT05715801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional oxygen therapy
Description: Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
Study NCT06198764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium for injection
Description: Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
Study NCT06198764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem for Injection
Description: Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
Study NCT06198764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem for Injection
Description: Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
Study NCT06198764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coly Mycin M Injectable Product
Description: Coly Mycin M is the originally marketed colistimethate sodium for injection.
Study NCT04512742 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biting by Phlebotomus duboscqi infected with Leishmania major
Description: The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only \< 6 subjects develop PCCL lesions, then an adaptive design will be followed.
Study NCT06308978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: FT819 will be administered as a single-dose intravenous (IV) infusion at planned dose levels.
Study NCT06308978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an IV infusion at planned dose levels.
Study NCT06308978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Study NCT06308978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as an IV infusion at planned dose levels.
Study NCT06128863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab, Eftilagimod alpha
Description: Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
Study NCT05117840 — intervention group
Intervention type: DEVICE
Intervention: Low-dose CT scan
Description: Standard of care screening for individuals at high-risk of lung cancer
Study NCT04818320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Day 1: 1800mg BD, day 2-5: 800mg BD
Study NCT05880693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group 1 received dexmedetomidine
Study NCT05880693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: the group 2 received magnesium sulfate
Study NCT06394336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening
Description: Strengthening exercises for the intrinsic muscles of the foot and hips
Study NCT06394336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (oral analgesic/anti-inflammatory drug)
Description: oral analgesic/anti-inflammatory drug. Education.
Study NCT06053593 — intervention group
Intervention type: DEVICE
Intervention: Testing of self collected urine
Description: Each PWD will test their self-collected urine.
Study NCT06053593 — intervention group
Intervention type: DEVICE
Intervention: Labeling Evaluation
Description: Each PWD will complete a labeling evaluation.
Study NCT06053593 — intervention group
Intervention type: DEVICE
Intervention: Urine Control testing
Description: Each PWD will test four urine control solutions.
Study NCT05457842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intradermal injection
Study NCT04971694 — intervention group
Intervention type: OTHER
Intervention: No interventions or procedures
Description: This is a retrospective observational study and data will be collected from the subject's existing medical record. No interventions or procedures will be required for this study.
Study NCT06264180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vusolimogene Oderparepvec
Description: Genetically modified Herpes Simplex Type 1 Virus.
Study NCT05935267 — intervention group
Intervention type: PROCEDURE
Intervention: thoracic irrigation
Description: We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.
Study NCT06247098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus Lift augmentation
Description: Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)
Study NCT06247098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Lift augmentation
Description: Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)
Study NCT06247098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography systems (CBCT)
Description: An research only use of CBCT at visit 2 to review healing status.
Study NCT06247098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cone-beam computed tomography systems (CBCT)
Description: An research only use of CBCT at visit 2 to review healing status.
Study NCT04965493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral
Study NCT04965493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral
Study NCT04965493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Oral
Study NCT04965493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV)
Study NCT04965493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous (IV)
Study NCT04785287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 Monoclonal Antibody BMS-986218
Description: Given IV
Study NCT04785287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04785287 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06264180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Anti-PD-1 Monoclonal Antibody
Study NCT06264180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 Monoclonal Antibody
Study NCT06264180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Relatlimab
Description: Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
Study NCT06298032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olamkicept Part A
Description: Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg
Study NCT06298032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olamkicept Part B
Description: Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg
Study NCT06298032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT06345872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Includes 8 weekly sessions of CBT-I and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
Study NCT06345872 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Includes 8 weekly sessions of standard treatment and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
Study NCT06345872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapered Withdrawal
Description: Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
Study NCT06345872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tapered Withdrawal
Description: Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
Study NCT06264180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A programmed death receptor-1 (PD-1)-blocking antibody indicated.
Study NCT06264180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent chemotherapy
Description: Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
Study NCT05511662 — intervention group
Intervention type: OTHER
Intervention: PRO follow up
Description: On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
Study NCT06103760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esketamine Nasal Spray [Spravato]
Description: This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
Study NCT05079230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously (IV)
Study NCT05079230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablets administered orally
Study NCT05079230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venetoclax
Description: Tablets administered orally
Study NCT05079230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
Study NCT05079230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
Study NCT05079230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magrolimab Placebo
Description: Administered intravenously (IV)
Study NCT05256303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Hospital care
Description: Patients receive hospital-level care in their home
Study NCT05256303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Hospital care
Description: Patients receive hospital-level care in the hospital.
Study NCT06534164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full/High Tech Telerehabilitation decision support system
Description: The TeleRehaB DSS intervention includes HOLOBalance balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme.
Study NCT06534164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic/Low Tech Telerehabilitation decision support system
Description: The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme.
Study NCT06534164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OTAGO Home exercise program
Description: balance rehabilitation program
Study NCT06534164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation program
Description: vestibular rehabilitation and dizziness program
Study NCT05513170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Densah Burs in closed sinus lift
Description: Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
Study NCT04926701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 single dose
Description: Single ascending doses of inhaled ETD001
Study NCT05513170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed sinus lift using osteotomes
Description: Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
Study NCT04926701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo single dose
Description: Single doses of inhaled placebo
Study NCT04926701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 multiple twice daily doses
Description: Ascending doses of inhaled ETD001 administered twice daily
Study NCT04926701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple twice daily doses
Description: Doses of inhaled placebo administered twice daily
Study NCT04926701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 multiple once daily doses
Description: Doses of inhaled ETD001 administered once daily
Study NCT04926701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple once daily doses
Description: Doses of inhaled placebo administered once daily
Study NCT06273709 — intervention group
Intervention type: DEVICE
Intervention: Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner
Description: (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
Study NCT05462717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6291
Description: Oral tablet once or twice a day
Study NCT06406010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5mg/ml 20ml
Description: administered in a pericapsular nerve group (PENG) block
Study NCT06406010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: administered in a pericapsular nerve group (PENG) block
Study NCT05716100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 Capsules
Study NCT05716100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study NCT05623007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
Study NCT04775316 — intervention group
Intervention type: DEVICE
Intervention: Leukomed T / Tplus skin sensitive treatment
Description: Application of sterile wound dressing.
Study NCT05343273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: taking a blood sample
Description: blood collection for routine biochemical analysis
Study NCT05718544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
Study NCT05718544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
Study NCT05718544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Study NCT05718544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.